Objectives: To compare recurrence rates between patients with mismatch repair proficient (pMMR) and MMR deficient (dMMR) high intermediate risk (HIR) endometrial cancer Methods: Adult women with HIR endometrial cancer diagnosed between January 1, 2016, and December 31, 2018, were identified from UC...
鈥塱mmune cells (p鈥?鈥?.0007) occupying the tumor compared to mismatch repair-proficient endometrial cancers. There was no significant difference in CD68鈥?鈥塼umor-associated macrophages infiltration between the two groups. Endometrial cancers with tumor PD-L1 expression also showed significantly ...
Background Mismatch repair (MMR) system has been implicated in the response of mammalian cells to ionizing radiation and DNA damaging agents. We investigated the value of the MMR system in predicting response to adjuvant therapy in endometrial cancer. Methods This was a single institution ...
Cross-talk between MMR and NER, the predominant pathway for the repair of UV damage, may also operate. Msh2−/− mice exhibit an increased predisposition to skin cancer in response to UVB exposure that is enhanced when mice are additionally defective for the NER Xpc gene (Meira et al.,...
Purpose: To evaluate mismatch repair (MMR) status in a series of high-grade endometrial carcinomas and correlate it with several clinicopathological characteristics and with survival. Methods: One hundred and one patients with high-grade endometrial carcinoma, both of endometrioid and of non-endometrioi...
Reflex mismatch repair immunohistochemistry (MMR IHC) testing for MLH1, PMS2, MSH2 and MSH6 is used to screen for Lynch syndrome. Recently MMR-deficiency (MMRd) has been approved as a pan-cancer predictive biomarker for checkpoint inhibitor therapy, leading to a vast increase in the use of ...
MLH1, MutL homolog 1; MSH2, MutS protein homolog 2; MSH6, MutS homolog 6; MSI-H, microsatellite instability high; MSI-L, microsatellite instability low; MSI-S/MSS, microsatellite stable; NCI, National Cancer Institute; pMMR, proficient mismatch repair; PMS2, postmeiotic segregation increased 2...
Clinicopathological features of dMMR gynecological cancer In gynecological cancers, dMMR is most commonly seen in endometrial cancer. In the general population, the lifetime risk for endometrial cancer is 3%, while in patients with Lynch syndrome, it is 27–71% [30]. In endometrial cancers, the...
[50,51]. dMMR colon cancer cells were 2- to 2.5-fold resistant to TMZ than MMR-proficient cells[52]. The increases in cell survival of dMMRcolon cancer cell linesin comparison to MMR-proficient cells were 10-fold using 1 μMMNNG(N-methyl-N’-nitro-N-nitrosoguanidine) and 2-fold ...
Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically enables high evolvability